Pulmonx Corporation (LUNG) raises its price range from $14-16 to $17-18 per share and increases the number of offered shares from 6.67 million to 10 million.
The IPO of Oncorus, Inc. will take place on October 1, 2020. Oncorus is a clinical stage biopharmaceutical company focused on developing the next-generation viral immunotherapies to improve outcomes for cancer patients.
C4 Therapeutics is a biopharmaceutical company that uses natural regulation of protein levels in the body to develop new therapeutic candidates for the destruction of disease causing proteins in the treatment of cancer and other diseases.
The IPO of Pulmonx, Corp. will take place on September 30, 2020. Pulmonx is a a medical technology company that provides a minimally invasive treatment for patients with severe emphysema - a chronic obstructive pulmonary disease.